Key Clinical Summary: Advancing Pompe Care - Monitoring Subclinical Progression

This is a micro-learning module summary of a presentation by Prof. Pascal Laforêt which you can find here.
Before participating, please read our CME and disclosure information which can be found here.

This activity is supported by an independent medical educational grant from Amicus Therapeutics. This online education program has been designed for healthcare professionals globally (excluding the USA).

Holistic, Multimodal Monitoring in “Stable” Late-Onset Pompe Disease (LOPD)

Long-term registry and real-world data confirm that although most patients with LOPD initially stabilize or improve with enzyme replacement therapy (ERT), variability is substantial and secondary decline is common after 3–5 years.

Nearly half of treated patients may demonstrate suboptimal long-term response.

These data underscore the need for structured, multimodal monitoring - even in patients perceived as clinically “stable.”

1. Motor Function: Beyond the 6-Minute Walk Test

The 6-minute walk test (6MWT) remains the gold standard functional outcome in LOPD due to standardization, accessibility, and reproducibility.

However:

It does not differentiate skeletal from respiratory contributions
It poorly reflects upper limb involvement
It is confounded by age, sarcopenia, osteoporosis, and comorbidities

The 2-minute walk test (2MWT) may provide a pragmatic alternative with strong correlation to 6MWT performance.

Timed function tests (10-m walk, stair climb, chair rise) are recommended as part of minimal follow-up datasets and may detect subtle decline earlier than global walk distance.

Clinical Pearl: Stability in 6MWT does not exclude progressive diaphragmatic or axial muscle deterioration.

2. Quantitative Muscle MRI: Detecting Subclinical Progression

Muscle MRI is both diagnostic and prognostic in LOPD:

Characteristic pattern:

Posterior thigh involvement
Paraspinal muscle fat replacement
Scapular stabilizer involvement
“Bright tongue” sign

Quantitative advances:

Fat fraction measurement (Dixon techniques)
Cross-sectional area and volume quantification
Mercury score grading

EPOC guidance highlights increasing emphasis on MRI as a biomarker of progression.

A fat fraction ≥20% in ≥2 muscles supports clinically meaningful structural involvement and may inform treatment decisions even without overt weakness.

Case Insight: In pre-symptomatic patients with preserved strength and normal 6MWT, progressive fat infiltration and emerging supine VC decline preceded clinical deterioration.

Clinical Pearl: MRI often detects progression before measurable functional loss.

3. Diaphragm Assessment: The Most Sensitive Early Marker

Respiratory involvement may be clinically silent yet progressive.

Mandatory assessment:

Forced vital capacity (FVC) in sitting and supine positions
A >20% drop in supine VC indicates diaphragmatic dysfunction

Additional tools:

Maximal inspiratory/expiratory pressures (MIP/MEP)
Blood gas analysis (hypercapnia = late sign)
Sleep studies when indicated

Emerging techniques:

Diaphragm ultrasound (thickness and excursion)
Chest/diaphragm MRI
3D magnetic resonance spirometry and optoelectronic plethysmography

Key Teaching Point (Polling Case): In patients with preserved sitting VC and minimal limb weakness, decline in supine VC was the most decisive marker guiding ERT discussions.

4. Patient-Reported Outcomes (PROs): Bridging Function and Experience

LOPD-specific and generic PROs capture patient-perceived burden and expectations:

SF-36, PROMIS
R-PACT (Pompe-specific functional scale)

These tools identify fatigue, endurance limitations, and daily activity constraints not fully captured by objective measures.

Clinical Pearl: Discordance between stable objective metrics and worsening patient-reported function may signal early decline.

5. Digital Monitoring and Emerging Biomarkers

Digital tools (mobile applications, remote self-assessment platforms) are evolving to:

Enable real-time symptom tracking
Strengthen communication with reference centers
Monitor activity and fatigue trends

Biochemical markers (CK, urine Glc4) have limited sensitivity and variability, particularly in adults.

They should not be used in isolation to determine stability or progression.

Integrating Multimodal Data for Individualised Optimisation

Holistic monitoring allows clinicians to:

Detect subclinical diaphragm decline
Quantify structural muscle deterioration
Identify discordant trajectories (stable limb strength but worsening respiratory metrics)
Recognize secondary decline during long-term ERT

This integrated approach supports:

Earlier initiation of therapy in pre-symptomatic progression
Timely optimisation or consideration of switch in poor responders
Patient-centered shared decision-making

Practical Monitoring Framework for “Stable” LOPD

Every 6–12 months:

6MWT or 2MWT
Timed functional tests
FVC sitting and supine (mandatory)
PRO assessment

Periodically (e.g., annually or biannually):

Quantitative muscle MRI
MIP and MEP should be performed at the same time of Pulmonary function tests, although less discriminant than FVC
Sleep assessment if indicated

After therapy initiation or switch:

Reassessment at 3–6 months and continued structured monitoring

Take-Home Messages

“Stable” LOPD is often only superficially stable.
Supine VC decline is an early, high-impact marker of progression.
Quantitative muscle MRI detects structural deterioration before clinical loss.
Functional, imaging, respiratory, and patient-reported data must be integrated—not interpreted in isolation.
Multimodal monitoring enables individualized supportive strategies and pharmacologic optimisation.

This structured, longitudinal approach transforms reactive management into proactive, precision care in LOPD.

Content accurate at the time of publication.